Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12 Week Double-blind, Randomised, Placebo-controlled, Modified Dose-escalation Trial to Investigate Safety, Efficacy, and Pharmacokinetics of BIRT 2584XX Tablets at Doses of 100, 300 and 500 mg Administered Once Daily in Patients With Moderate to Severe Psoriasis With a 12 Week Treatment Extension

NCT00333411 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT00333411
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00333411 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12 Week Double-blind, Randomised, Placebo-controlled, Modified Dose-escalation Trial to Investigate Safety, Efficacy, and Pharmacokinetics of BIRT 2584XX Tablets at Doses of 100, 300 and 500 mg Administered Once Daily in Patients With Moderate to Severe Psoriasis With a 12 Week Treatment Extension
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2006
Completion date
Not reported
Enrollment
360 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis